Related Experiment Video
Updated: Aug 9, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes
Sean Sachdev1,2, Crismita Dmello2,3, Adam M Sonabend2,3
1Department of Radiation Oncology, Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.
Abstract:
Isocitrate dehydrogenase 1-mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes. See related article by Carney et al., p. 1763.

